The addition of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) to ET has recently been associated with improved progression-free survival (PFS) and, in some cases, overall survival (OS) in patients with invasive ER+ breast cancer. The gene discussed is CDK4; the disease is breast cancer.